<DOC>
	<DOCNO>NCT00548574</DOCNO>
	<brief_summary>The primary objective study compare percentage subject remission 8 week treatment SPD476 , 2.4 g/day daily v placebo SPD476 4.8 g/day daily versus placebo</brief_summary>
	<brief_title>Efficacy Safety Two Doses SPD476 ( Mesalazine ) 2.4g 4.8g Once Daily , With Reference Asacol 0.8g Three Times Daily Subjects With Acute , Mild Moderate Ulcerative Colitis</brief_title>
	<detailed_description />
	<mesh_term>Ulcer</mesh_term>
	<mesh_term>Colitis , Ulcerative</mesh_term>
	<mesh_term>Colitis</mesh_term>
	<mesh_term>Mesalamine</mesh_term>
	<criteria>newly diagnose relapse mild moderate UC ( score 410 ( inclusive ) UCDAI scale , sigmoidoscopy score = &gt; 1 PGA &lt; =2 ) compatible histology female eligible postmenopausal , surgically sterile negative urine pregnancy test screen adequate contraception subject relapse UC relapse &gt; 6 week prior baseline subject relapse maintenace therapy dose mesalazine = &gt; 2g/day subject unsuccessfully treat current relapse steroid mesalazine dose &gt; 2g/day subject Crohn 's disease , proctitis , bleed disorder , active peptic ulcer disease , previous colonic surgery , immediate risk toxic megacolon stool culture positive enteric pathogen subject use systemic rectal steroid within last 4 week , immunosuppressant wihtin last 6 week antiinflammatory drug repeat basis within 7 day prior baseline visit subject hypersensitivity salicylates subject moderate/severe renal impairment</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2007</verification_date>
</DOC>